References
- Delay J, Deniker P. Drug-induced extrapyramidal syndrome. Handbook of clinical neurology. New York: Elsevier, PJ Visken, GW Bruyn, 1968; 248–266
- Gurrera RJ, Chang SS, Romero JA. A comparision of diagnostic criteria for neuroleptic malignant syndrome. Journal of Clinical Psychiatry 1992; 53: 56–62
- Smego RA, Durack DT. The neuroleptic malignant syndrome. Archives of Internal Medicine 1982; 142: 1183–1185
- Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatrica Scandinavica 1986; 73: 337–347
- Lavie CJ, Olmsted TR, Ventura HO. Neuroleptic malignant syndrome. An underdiagnosed reaction to neuroleptic agents? Postgraduate Medicine 1986; 80: 171–178
- Addonizio G, Susman VL, Roth SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. American Journal of Psychiatry 1986; 143: 1587–1590
- Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. American Journal of Psychiatry 1989; 146: 717–725
- Caroff SN. The neuroleptic malignant syndrome. Journal of Clinical Psychiatry 1982; 41: 79–83
- Zubenko D, Pope HG. Management of a case of neuroleptic malignant syndrome with bromocriptine. American Journal of Psychiatry 1983; 140: 1619–1620
- Sternberg DE. Neuroleptic malignant syndrome: the pendulum swings. American Journal of Psychiatry 1986; 143: 1273–1275
- Langstone JW, Forno LS. The hypothalamus in Parkinson's disease. Annual of Neurology 1978; 3: 129–133
- Henderson VW, Wooten GF. Neuroleptic malignant syndrome: a pathogenic role for dopamine receptor blockade?. Neurology 1981; 31: 132–137
- Downey GP, Caroff S, Rosenberg H, Gerber JC, Heiman-Patterson TD, Aronson MD. Neuroleptic malignant syndrome. Patient with unique clinical and physiologic features. American Journal of Medicine 1984; 77: 338–340
- Misiaszek JJ, Potter RL. Atypical neuroleptic malignant syndrome responsive to conservative management. Psychosomatics 1985; 26: 62–66
- Conlon P. The spectrum concept of neuroleptic toxicity. American Journal of Psychiatry 1986; 143: 811
- Pope HG, Keck PE, McElory SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. American Journal of Psychiatry 1986; 143: 1227–1233
- Guze BH, Baxter LR. Current concept: neuroleptic malignant syndrome. New England Journal of Medicine 1985; 313: 163–166
- Burke RE, Fahn S, Mayeux R. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington's disease. Neurology 1981; 31: 1022–1026
- Simpson DM, Davis GC. Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine. American Journal of Psychiatry 1984; 141: 796–797
- Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignant-like syndrome due to levodopa therapy withdrawal. Journal of the American Medical Association 1985; 254: 2792
- Fogel BS, Goldberg RJ. Neuroleptic malignant syndrome. New England Journal of Medicine 1985; 313: 1292